Global Information
회사소개 | 문의
SALE

말초동맥질환(PAD) : 주요 22개국 시장 예측

Epiomic Epidemiology Series: Peripheral Arterial Disease Forecast in 22 Major Markets 2018-2028

리서치사 Black Swan Analysis
발행일 2018년 08월 상품 코드 353260
페이지 정보 영문 102 Pages
가격
US $ 5,800 US $ 5,104 ₩ 5,800,000 PDF by E-mail (Single User License)
US $ 8,700 US $ 7,656 ₩ 8,700,000 PDF by E-mail (Site License)
US $ 10,400 US $ 9,152 ₩ 10,400,000 PDF by E-mail (Global License)


말초동맥질환(PAD) : 주요 22개국 시장 예측 Epiomic Epidemiology Series: Peripheral Arterial Disease Forecast in 22 Major Markets 2018-2028
발행일 : 2018년 08월 페이지 정보 : 영문 102 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

말초동맥질환(PAD)은 말초동맥의 폐색이며, 개인의 전신성 죽상동맥경화 부담의 측정 기준으로서 여겨지고 있습니다. 또한 일반적으로 PAD는 발목상완혈압지수(ABPI) 0.9 이하로 정의됩니다. PAD는 말초동맥 폐색성 질환, 폐색성 동맥경화증, 하지 폐색성 질환 및 말초혈관 질환으로도 알려져 있습니다.

주요 22개국 시장(미국, 캐나다, 프랑스, 독일, 이탈리아, 스페인, 영국, 폴란드, 네덜란드, 스웨덴, 그리스, 러시아, 터키, 사우디아라비아, 일본, 중국, 한국, 인도, 호주, 브라질, 멕시코, 아르헨티나)의 말초동맥질환(PAD: Peripheral Arterial Disease) 현재 환자수(성별, 연령 코호트별)에 대해 조사 분석했으며, 현재 유병률, 질환 개요, 위험인자, 질환의 진단과 예후, 주요 증상과 합병증 등의 정보를 정리하여 전해드립니다.

도표

서론

병인

위험인자와 예방

질환의 진단

변이 : 지역/민족별

질환의 예후와 임상 경과

질환에 관련된 주요 합병증/특징

환자수 정량화 방법

말초동맥질환(PAD) 최대 환자수

말초동맥질환(PAD) 특징

  • 환자 파라미터
  • 말초동맥질환(PAD) 환자의 동반질병

약어

기타 서비스 및 솔루션

  • 보고서 및 출판물
  • 온라인 역학 데이터베이스
  • 온라인 약가 데이터베이스

참고 문헌

부록

LSH 18.08.01

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Peripheral Arterial Disease (PAD) in 22 Major Markets

Peripheral Arterial disease (PAD) is an occlusion of the peripheral arteries and is widely viewed as a measure of an individual's global systemic atherosclerotic burden. Typically, it is defined as an ankle-brachial pressure index (APBI) ratio of <0.9. PAD can also be known as peripheral arterial occlusive disease, arteriosclerosis obliterans, lower extremity occlusive disease and peripheral vascular disease.

This report provides the current prevalent population for PAD across 22 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Sweden, Greece, Russia, Turkey, Saudi Arabia, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main patient features and co-morbidities of PAD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for PAD include:

Hypertension

Family history of PAD

Dyslipidaemia

Obesity

Diabetes

Lower limb ischaemia

Myocardial infarction

Coronary artery disease (CAD)

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

Ability to quantify patient populations in global PAD market to target the development of future products, pricing strategies and launch plans.

Further insight into the prevalence of the subdivided types of PAD and identification of patient segments with high potential.

Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

Better understanding on the impact of specific co-morbid conditions on the prevalent population of PAD patients.

Identification of PAD patient sub-populations that require treatment.

Better understanding of the specific markets that have the largest number of PAD patients.

CONTENTS

  • LIST OF TABLES AND FIGURES
  • INTRODUCTION
  • CAUSE OF THE DISEASE
  • RISK FACTORS & PREVENTION
  • DIAGNOSIS OF THE DISEASE
  • VARIATION BY GEOGRAPHY/ETHNICITY
  • DISEASE PROGNOSIS & CLINICAL COURSE
  • KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
  • METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
  • TOP-LINE PREVALENCE FOR PERIPHERAL ARTERIAL DISEASE
  • FEATURES OF PERIPHERAL ARTERIAL DISEASE
  • PATIENT PARAMETERS
  • COMORBIDITIES OF PAD PATIENTS
  • COMORBIDITIES OF PAD PATIENTS WITH INTERMITTENT CLAUDICATION
  • ABBREVIATIONS USED IN THE REPORT
  • OTHER BLACK SWAN SERVICES & SOLUTIONS
  • REPORTS & PUBLICATIONS
  • ONLINE EPIDEMIOLOGY DATABASES
  • ONLINE PHARMACEUTICAL PRICING DATABASE
  • REFERENCES
  • APPENDIX

LIST OF TABLES AND FIGURES

  • Table 1. Fontaine Classification System for PAD
  • Table 2. Rutherford Classification System for PAD
  • Table 3. Society for Vascular Surgery WIfI for PAD classification
  • Table 4. Society for Vascular Surgery TASC II Classification for PAD
  • Table 5. Prevalence of PAD, total (000s)
  • Table 6. Prevalence of PAD, males (000s)
  • Table 7. Prevalence of PAD, females (000s)
  • Table 8. Patients with PAD by severity, total (000s)
  • Table 9. Patients with PAD by size of vessels involved, total (000s)
  • Table 10. Patients with PAD by presence of symptoms, total (000s)
  • Table 11. PAD patients with intermittent claudication by IC profile, total (000s)
  • Table 12. PAD patients with intermittent claudication by grade of symptoms, total (000s)
  • Table 13. Incidence of critical limb ischaemia in PAD patients with intermittent claudication, total (000s)
  • Table 14. PAD patients with acute limb ischaemia by 1-year outcome, total (000s)
  • Table 15. Patients with PAD by BMI status, total (000s)
  • Table 16. Patients with PAD by total cholesterol level, total (000s)
  • Table 17. Patients with PAD by LDL level, total (000s)
  • Table 18. Patients with PAD by smoking status, total (000s)
  • Table 19. PAD patients with diabetes, total (000s)
  • Table 20. PAD patients with arterial hypertension, total (000s)
  • Table 21. PAD patients with chronic heart failure, total (000s)
  • Table 22. PAD patients with coronary heart disease, total (000s)
  • Table 23. PAD patients with angina, total (000s)
  • Table 24. PAD patients with stroke, total (000s)
  • Table 25. PAD patients with elevated CRP, total (000s)
  • Table 26. PAD patients with intermittent claudication and diabetes, total (000s)
  • Table 27. PAD patients with intermittent claudication and hypertension, total (000s)
  • Table 28. PAD patients with intermittent claudication and hyperlipidaemia, total (000s)
  • Table 29. PAD patients with intermittent claudication and a history of myocardial infarction, total (000s)
  • Table 30. PAD patients with intermittent claudication and angina, total (000s)
  • Table 31. Abbreviations and acronyms used in the report
  • Table 32. USA prevalence of PAD by 5-yr age cohort, males (000s)
  • Table 33. USA prevalence of PAD by 5-yr age cohort, females (000s)
  • Table 34. Canada prevalence of PAD by 5-yr age cohort, males (000s)
  • Table 35. Canada prevalence of PAD by 5-yr age cohort, females (000s)
  • Table 36. France prevalence of PAD by 5-yr age cohort, males (000s)
  • Table 37. France prevalence of PAD by 5-yr age cohort, females (000s)
  • Table 38. Germany prevalence of PAD by 5-yr age cohort, males (000s)
  • Table 39. Germany prevalence of PAD by 5-yr age cohort, females (000s)
  • Table 40. Italy prevalence of PAD by 5-yr age cohort, males (000s)
  • Table 41. Italy prevalence of PAD by 5-yr age cohort, females (000s)
  • Table 42. Spain prevalence of PAD by 5-yr age cohort, males (000s)
  • Table 43. Spain prevalence of PAD by 5-yr age cohort, females (000s)
  • Table 44. UK prevalence of PAD by 5-yr age cohort, males (000s)
  • Table 45. UK prevalence of PAD by 5-yr age cohort, females (000s)
  • Table 46. Poland prevalence of PAD by 5-yr age cohort, males (000s)
  • Table 47. Poland prevalence of PAD by 5-yr age cohort, females (000s)
  • Table 48. Netherlands prevalence of PAD by 5-yr age cohort, males (000s)
  • Table 49. Netherlands prevalence of PAD by 5-yr age cohort, females (000s)
  • Table 50. Sweden prevalence of PAD by 5-yr age cohort, males (000s)
  • Table 51. Sweden prevalence of PAD by 5-yr age cohort, females (000s)
  • Table 52. Greece prevalence of PAD by 5-yr age cohort, males (000s)
  • Table 53. Greece prevalence of PAD by 5-yr age cohort, females (000s)
  • Table 54. Russia prevalence of PAD by 5-yr age cohort, males (000s)
  • Table 55. Russia prevalence of PAD by 5-yr age cohort, females (000s)
  • Table 56. Turkey prevalence of PAD by 5-yr age cohort, males (000s)
  • Table 57. Turkey prevalence of PAD by 5-yr age cohort, females (000s)
  • Table 58. Saudi Arabia prevalence of PAD by 5-yr age cohort, males (000s)
  • Table 59. Saudi Arabia prevalence of PAD by 5-yr age cohort, females (000s)
  • Table 60. Japan prevalence of PAD by 5-yr age cohort, males (000s)
  • Table 61. Japan prevalence of PAD by 5-yr age cohort, females (000s)
  • Table 62. China prevalence of PAD by 5-yr age cohort, males (000s)
  • Table 63. China prevalence of PAD by 5-yr age cohort, females (000s)
  • Table 64. South Korea prevalence of PAD by 5-yr age cohort, males (000s)
  • Table 65. South Korea prevalence of PAD by 5-yr age cohort, females (000s)
  • Table 66. India prevalence of PAD by 5-yr age cohort, males (000s)
  • Table 67. India prevalence of PAD by 5-yr age cohort, females (000s)
  • Table 68. Australia prevalence of PAD by 5-yr age cohort, males (000s)
  • Table 69. Australia prevalence of PAD by 5-yr age cohort, females (000s)
  • Table 70. Brazil prevalence of PAD by 5-yr age cohort, males (000s)
  • Table 71. Brazil prevalence of PAD by 5-yr age cohort, females (000s)
  • Table 72. Mexico prevalence of PAD by 5-yr age cohort, males (000s)
  • Table 73. Mexico prevalence of PAD by 5-yr age cohort, females (000s)
  • Table 74. Argentina prevalence of PAD by 5-yr age cohort, males (000s)
  • Table 75. Argentina prevalence of PAD by 5-yr age cohort, females (000s)
Back to Top
전화 문의
이용안내
 
BCC Research